Jun Liang

发表

Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review

Xiaotong Lu, J. Liang, Yunsong Liu, 2022, Frontiers in Immunology.

HIPPO signaling-related signature for predicting prognosis and therapeutic response in gastric cancer

Rui Wei, Q. Lian, Hao Chen, 2023, Frontiers in Pharmacology.

Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma

Chuanhao Tang, Hao Zhang, Wei-ran Xu, 2022, Frontiers in Oncology.

Safety and efficacy analysis of chemoradiotherapy/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis

Peng Wang, J. Liang, Yu Zhang, 2022, BMC gastroenterology.

Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature

Jianyang Wang, Zongmei Zhou, Q. Feng, 2022, Medicine.

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer

Chao Meng, Yansong Lin, Juanjuan Song, 2023, Frontiers in Endocrinology.

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Lujun Zhao, Junling Li, Wei Jiang, 2019, BMC Cancer.

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma

Wenjing Zhang, Yali Li, H. Tian, 2022, Frontiers in Pharmacology.

Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

L. Yang, Huadan Xue, Zhengyu Jin, 2022, Liver Cancer.

Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes

A. Daemen, J. Giltnane, L. Friedman, 2019, Poster Session Abstracts.

Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

W. Feng, H. Hong, Xiaotao Huang, 2022, Journal of Experimental & Clinical Cancer Research.

Pneumatosis intestinalis post steroid use in a patient with immune-related adverse events: Case report, literature review and FAERS analysis

Chuanhao Tang, Ting-ting Zhang, Z. Zhao, 2023, Frontiers in Pharmacology.

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

Y. Ba, Shiying Yu, Z. Guan, 2011, Chinese journal of cancer.

The E cacy and Safety of Fruquintinib Plus PD-1 Inhibitor in ≥3 line MSS Metastatic Colorectal Cancer Patients

Xiang Wang, Xian-Bao Wang, Li Lin, 2021 .

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial

Y. Ba, Jianming Xu, Jun Liang, 2011, Chinese journal of cancer.